Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3104-3110

  Acosta, Edward P ^a   Kendall, Michelle A ^b   Gerber, John G ^c   Alston Smith, Beverly ^d   Koletar, Susan L ^e   Zolopa, Andrew R ^f   Agarwala, Sangeeta ^g   Child, Michael ^g   Bertz, Richard ^g   Hosey, Lara ^h   Haas, David W ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f STANFORD UNIVERSITY   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CYTOCHROME P450 3A; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; SUPERINFECTION; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RIFAMPIN; TUBERCULOSIS;

EID: 35948936336     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00341-07     Document Type: Article

References (19)

1. Beutler, E., T. Gelbart, and A. Demina. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism. Proc. Natl. Acad. Sci. USA 95:8170-8174.
2. Boffito, M., M. Kurowski, G. Kruse, A. Hill, A. A. Benzie, M. R. Nelson, et al. 2004. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 18:1291-1297.
3. Bristol-Myers Squibb Company. 2006. Reyataz (atazanavir sulfate) prescribing information. Bristol-Myers Squibb Company, Princeton, NJ.
4. Reference deleted.
5. Burger, D., S. Agarwala, M. Child, A. Been-Tiktak, Y. Wang, and R. Bertz. 2005. Effect of rifampin on steady-state pharmacokinetics of atazanavir and ritonavir in healthy volunteers. Antimicrob. Agents Chemother. 50:3336-3342.
6. Cohen, C., L. Nieto-Cisneros, C. Zala, W. J. Fessel, J. Gonzalez-Garcia, A. Gladysz, R. McGovern, E. Adler, and C. McLaren. 2005. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr. Med. Res. Opin. 21:1683-1692.
7. Grange, S., M. Schutz, C. Schmitt, et al. 2005. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa, abstr. 35. Sixth Int. Workshop Clin. Pharmacol. HIV Ther., Montreal, Quebec, Canada, 28 to 30 April 2005.
8. Johnson, M., B. Grinsztejn, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, K. Lichtenstein, V. Wirtz, A. Rightmire, L. Odeshoo, and C. McLaren. 2006. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20:711-718.
9. Johnson, M., B. Grinsztejn, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, K. Lichtenstein, A. Rightmire, S. Sankoh, and R. Wilber. 2005. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19:685-694.
10. Murphy, R. L., I. Sanne, P. Cahn, P. Phanuphak, L. Percival, T. Kelleher, and M. Giordano. 2003. Dose-Tanging, Tandomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17:2603-2614.
11. Noor, M. A., R. A. Parker, E. O'Mara, D. M. Grasela, A. Currie, S. L. Hodder, F. T. Fiedorek, and D. W. Haas. 2004. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 18:2137-2144.
12. O'Mara, E., D. Randall, J. Passarell, S. Steinberg, E. Ludwig, and D. Grasela. 2003. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects, abstr. 3051. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
13. Panel on Clinical Practices for Treatment of HIV Infection. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. U.S. Department of Health and Human Services, Washington, DC.
14. Raijmakers, M. T., P. L. Jansen, E. A. Steegers, and W. H. Peters. 2000. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J. Hepatol. 33:348-351.
15. Sanne, I., P. Piliero, K. Squires, A. Thiry, and S. Schnittman. 2003. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. 32:18-29.
16. Squires, K., A. Lazzarin, J. M. Gatell, W. G. Powderly, V. Pokrovskiy, J. F. Delfraissy, J. Jemsek, A. Rivero, W. Rozenbaum, S. Schrader, M. Sension, A. Vibhagool, A. Thiry, and M. Giordano. 2004. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36:1011-1019.
17. Swainston, H. T., and L. J. Scott. 2005. Atazanavir: a review of its use in the management of HIV infection. Drugs 65:2309-2336.
18. Wood, R., P. Phanuphak, P. Cahn, V. Pokrovskiy, W. Rozenbaum, G. Pantaleo, M. Sension, R. Murphy, M. Mancini, T. Kelleher, and M. Giordano. 2004. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J. Acquir. Immune Defic. Syndr. 36:684-692.
19. World Health Organization. 2006. Tuberculosis fact sheet no. 104 (updated March 2007). World Health Organization, Geneva, Switzerland.